Earnings Ahead

CASI - CASI Pharmaceuticals, Inc.

2.73 -0.09 -3.19

CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals, Inc.

About

Profile


Headquarters


Intraday

High
-
Low
-

52-week

High
-
Low
-

CASI



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Chinese pharmas and biotechs risk of delisting averted as US regulators review audits
  • CASI spikes as CAR-T therapy undergoes review in China for leukemia
  • CASI Pharmaceuticals GAAP EPS of -$0.38 beats by $0.08, revenue of $10.21M beats by $0.3M
  • Casi to sell stake in Juventas to Jiadao Gongcheng for ~RMB240.87M
  • CASI Pharmaceuticals GAAP EPS of -$0.56, revenue of $8.57M beats by $0.7M
  • CASI Pharmaceuticals Q2 2022 Earnings Preview
  • CASI Pharmaceuticals up 42% premarket ahead of reverse stock split
  • Casi Pharmaceuticals stock rises on license/equity stake deal with China's Tianshi
  • CASI Pharmaceuticals GAAP EPS of -$0.06 beats by $0.03, revenue of $9.06M misses by $0.18M
  • CASI Pharmaceuticals Q1 2022 Earnings Preview
  • Casi Pharma extends losses as company drags into U.S. audit dispute
  • CASI Pharmaceuticals GAAP EPS of -$0.27 beats by $0.03, revenue of $30.17M beats by $0.09M
  • CASI renews distribution agreement for Evomela in China
  • CASI Pharmaceuticals sees Q4 revenue ahead of analysts estimates
  • CASI announces FDA’s Orphan Drug Designation for follicular lymphoma candidate
  • CASI's partner Juventas' CNCT19 for blood cancer gets FDA orphan drug status
  • CASI Pharmaceuticals receives Nasdaq notification for minimum bid price requirement
  • CASI Pharmaceuticals jumps 12% on repurchase of stock upto $10M
  • CASI gains on Chinese regulatory nod for clinical trials in non-Hodgkin's Lymphoma
  • CASI Pharma rises on insider purchases from CEO

Earnings History

Date EPS / Forecast Revenue / Forecast
November 12, 2021 -0.07 / -0.055 8.11M / 7.53M Beat!
August 12, 2021 -0.05 / -0.0725 7.16M / 6.02M Beat!
May 13, 2021 -0.11 / -0.06 5.74M / 5.05M Beat!
March 30, 2021 -0.12 / -0.07 4.82M / 4.57M Beat!
November 9, 2020 -0.14 / -0.055 4.24M / 3.44M Beat!
August 10, 2020 -0.09 / -0.08 2.67M / 3.75M
May 11, 2020 -0.09 / -0.11 3.41M / 788K
March 16, 2020 -0.13 / -0.11 1.36M / 1.16M Beat!
November 12, 2019 -0.1 / -0.11 2.79M / 724K
August 9, 2019 -0.16 / -0.09 2.79M / 0.85M Beat!
May 15, 2019 -0.09 / -0.09 615K / 615K
March 29, 2019 -0.1 / -0.08 2.79M / 250K
November 14, 2018 -0.1 / -0.04 2.79M / - Beat!
August 14, 2018 -0.07 / -0.07 - / -
March 29, 2018 - / -0.02 - / -
November 13, 2017 -0.03 / -0.04 - / -
August 14, 2017 - / -0.04 - / -
May 12, 2017 - / - - / -
March 27, 2017 -0.05 / -0.04 - / -
November 14, 2016 -0.03 / -0.07 - / -
Date Price Open High Low Vol Change ER
Mar 25 0.8503 0.8300
0.8750
0.8300
234.54K 2.84%
Mar 24 0.8268 0.8500
0.8532
0.8200
306.60K -2.33%
Mar 23 0.8465 0.8400
0.8805
0.8304
417.30K -0.41%
Mar 22 0.8500 0.8100
0.8500
0.8097
374.30K 5.42%
Mar 21 0.8063 0.8100
0.8300
0.7911
322.57K -1.67%
 
Mar 18 0.8200 0.8070
0.8350
0.8011
506.87K 0.61%
Mar 17 0.8150 0.8058
0.8459
0.7860
384.45K 0.62%
Mar 16 0.8100 0.8119
0.8430
0.8096
526.75K 1.39%
Mar 15 0.7989 0.8100
0.8349
0.7623
584.04K -3.64%
Mar 14 0.8291 0.8600
0.9100
0.8100
484.37K -8.89%
Mar 11 0.9100 0.8905
0.9326
0.8800
1.02M 1.19%
Mar 10 0.8993 0.9000
0.9000
0.8700
171.77K 0.17%
Mar 9 0.8978 0.8900
0.9299
0.8695
474.18K 1.99%
Mar 8 0.8803 0.8000
0.8999
0.8000
285.53K 7.35%
Mar 7 0.8200 0.8600
0.8679
0.8010
286.68K -2.96%
Mar 4 0.8450 0.8686
0.9099
0.8401
245.47K -3.98%
Mar 3 0.8800 0.8885
0.8993
0.8653
206.22K 0.26%
Mar 2 0.8777 0.8593
0.8900
0.8593
268.83K 0.89%
Mar 1 0.8700 0.8500
0.8899
0.8400
235.96K 3.33%
Feb 28 0.8420 0.8500
0.8649
0.8400
222.11K -3.24%